Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial

Li, Dapeng; Chi, Yihebali; Chen, Xiaohong; Ge, Minghua; Zhang, Yuan; Z, Guo; Wang, Jun; Chen, Jie; Zhang, Jiewu; Cheng, Ying; Li, Zhendong; Liu, Hui; Qin, Jianwu; Zhu, Jingqiang; Cheng, Ruochuan; Xu, Zhengang; Zheng, Xiangqian; Tang, Ping-zhang; Gao, Ming

doi:10.1158/1078-0432.ccr-20-2950

Cited by 74 publications

(59 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The toxicity of the treatment regimen was related to the treatment course. In the study of anlotinib as the second-line treatment for renal clear cell carcinoma (median PFS: 8.5 months) and as first-line treatment for medullary thyroid cancer (median PFS: 20.7 months), the incidence of dose adjustment was 11.9 and 32.2%, respectively (Ma et al, 2020;Li et al, 2021). Thirdly, this is a retrospective study, the adverse events might be underestimated for the incomplete records.…”

Section: Discussionmentioning

confidence: 93%

“…Anlotinib inhibits the FGFR phosphorylation with an IC 50 of 11.7 nM, stronger than sunitinib and sorafenib (Lin et al, 2018). In China, anlotinib has been approved for the treatment of non-small cell lung cancer, small cell lung cancer, medullary thyroid cancer, and soft tissue sarcoma (Chi et al, 2018;Han et al, 2018;Cheng et al, 2021;Li et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Anlotinib Alone or in Combination With Temozolomide in the Treatment of Recurrent High-Grade Glioma: A Retrospective Analysis

et al. 2021

View full text Add to dashboard Cite

Background: Anlotinib is a multi-target anti-angiogenic agent. This retrospective study aimed to evaluate the efficacy and safety of anlotinib alone or in combination with temozolomide for the treatment of recurrent high-grade glioma.Materials and Methods: The clinical data of patients with recurrent high-grade glioma treated with anlotinib alone or in combination with temozolomide in our cancer center were collected and analyzed. Treatment response was evaluated according to the response assessment for neuro-oncology criteria. Progression-free survival, progression-free survival at 6 months, overall survival, and overall survival at 12 months were evaluated by Kaplan–Meier method and compared by log-rank test.Results: Between August 2019 and December 2020, 31 patients with recurrent high-grade glioma (21 of grade 4 and 10 of grade 3) were enrolled in this study. Seventeen patients received anlotinib alone and 14 received anlotinib plus temozolomide. All patients were heavily treated, the median lines of previous treatments were 2, and the median Karnofsky score was 60. At the data cutoff date, the median progression-free survival was 4.5 months and the progression-free survival at 6 months was 43.5%. The median overall survival was 7.7 months, and the overall survival at 12 months was 26.7%. The progression-free survival at 6 months and the overall survival at 12 months for 21 patients with grade 4 glioma was 40.2 and 27.9%, respectively. The tumor objective response rate was 41.9% in all patients and 33.3% in patients with grade 4 glioma. No grade 3 or worse treatment-related adverse events were recorded during the treatment.Conclusion: Anlotinib alone or in combination with temozolomide showed encouraging efficacy and favorable tolerability in patients with recurrent high-grade glioma who had been heavily treated.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Anlotinib Alone or in Combination With Temozolomide in the Treatment of Recurrent High-Grade Glioma: A Retrospective Analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…If the disease progresses despite vandetanib or cabozantinib treatment, dacarbazine or combination chemotherapy can be administered [6,30]. Clinical studies for other novel multi-targeted TKIs, such as ponatinib (AP24534), anlotinib (AL3818), and TPX-0046, are ongoing in advanced or metastatic MTC [31][32][33].…”

Section: Article In Pressmentioning

confidence: 99%

Current Guidelines for Management of Medullary Thyroid Carcinoma

Kim

2021

Endocrinol Metab

View full text Add to dashboard Cite

Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor originating from the parafollicular cells. The diagnostic and therapeutic strategies for the condition are different from those used for well-differentiated thyroid cancer. Since the 2015 American Thyroid Association guidelines for the diagnosis and treatment of MTC, the latest, including the National Comprehensive Cancer Network and European Association for Medical Oncology guidelines have been updated to reflect several recent advances in the management of MTC. Advances in molecular diagnosis and postoperative risk stratification systems have led to individualized treatment and follow-up strategies. Multi-kinase inhibitors, such as vandetanib and cabozantinib, can prolong disease progression-free survival with favorable adverse effects. In addition, potent selective rearranged during transfection (RET) inhibitors (selpercatinib and pralsetinib) have shown a promising efficacy in recent clinical trials. This review summarizes the management of MTC in recent guidelines focused on sporadic MTC.

show abstract

“…A multicenter, randomized, double-blind, placebo-controlled phase IIB study investigated the usefulness of a novel MKI, anlotinib, in the therapy of locally advanced or metastatic MTCs. Drug treatment, compared to placebo, significantly improved the median PFS and ORR, with no significant difference in OS between the tested groups [ 161 ].…”

Section: Currently Used and Investigated Targeted Therapies In Tcsmentioning

confidence: 99%

Novel Inhibitor-Based Therapies for Thyroid Cancer—An Update

Ratajczak

Gawel

Godlewska

2021

IJMS

View full text Add to dashboard Cite

Thyroid cancers (TCs) are the most common tumors of the endocrine system and a constant rise in the number of TC cases has been observed for the past few decades. TCs are one of the most frequent tumors in younger adults, especially in women, therefore early diagnosis and effective therapy are especially important. Ultrasonography examination followed by fine needle biopsy have become the gold standard for diagnosis of TCs, as these strategies allow for early-stage detection and aid accurate qualification for further procedures, including surgical treatment. Despite all the advancements in detection and treatment of TCs, constant mortality levels are still observed. Therefore, a novel generation line of targeted treatment strategies is being developed, including personalized therapies with kinase inhibitors. Recent molecular studies on TCs demonstrate that kinase inhibitor-based therapies might be considered as the most promising. In the past decade, new kinase inhibitors with different mechanisms of action have been reported and approved for clinical trials. This review presents an up-to-date picture of new approaches and challenges of inhibitor-based therapies in treatment of TCs, focusing on the latest findings reported over the past two years.

show abstract

Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial

Cited by 74 publications

References 37 publications

Anlotinib Alone or in Combination With Temozolomide in the Treatment of Recurrent High-Grade Glioma: A Retrospective Analysis

Anlotinib Alone or in Combination With Temozolomide in the Treatment of Recurrent High-Grade Glioma: A Retrospective Analysis

Current Guidelines for Management of Medullary Thyroid Carcinoma

Novel Inhibitor-Based Therapies for Thyroid Cancer—An Update

Contact Info

Product

Resources

About